ArticleParasites & vectors2018
Efficacy of a novel mode of action of an indoor residual spraying product, SumiShield® 50WG against susceptible and resistant populations of Anopheles gambiae (s.l.) in Benin, West Africa.
Article in Parasites & vectors, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of indoor residual spray efficacy and effectiveness against Plasmodium falciparum in Africa.Nature communications · 2018Pooled it
- Residual efficacy of SumiShield™ 50WG for indoor residual spraying in Ethiopia.Malaria journal · 2022Trial
- Trial
- Can dual active ingredient Interceptor® G2 insecticide-treated net (ITN) replace indoor residual spraying (IRS) efficiently? A case study in Sakassou, Côte d'Ivoire.Parasites & vectors · 2026Article
- Determination of the preliminary discriminating concentration of broflanilide against malaria vector mosquito Anopheles gambiae by multi-centre susceptibility testing.Malaria journal · 2026Article
- Control of pyrethroid-resistant Anopheles gambiae s.l. with Sovrenta® 15WP, a new isoxazoline insecticide for indoor residual spraying.Malaria journal · 2026Article
- Residual efficacy of indoor residual spraying using clothianidin (SumiShield 50WG) under experimental huts and field conditions in Senegal.Malaria journal · 2026Article
- Adjusting vector surveillance for human behaviors reveals Anopheles funestus drove a resurgence in malaria despite IRS with clothianidin in Uganda.Scientific reports · 2025Article
- The Comparative Performance of Klypson 500WG and 2GARD-WP Sprayed on Different Wall Surfaces AgainstTropical medicine and infectious disease · 2025Article
- Indoor Residual Spraying With Fludora Fusion for Malaria Control in Pyrethroid-Resistant Areas of Gujarat, India: A Community-Randomized Trial.Journal of tropical medicine · 2025Article
- Substrate promiscuity of key resistance P450s confers clothianidin resistance while increasing chlorfenapyr potency in malaria vectors.Cell reports · 2024Article
- An observational analysis of the impact of indoor residual spraying in two distinct contexts of Burkina Faso.Malaria journal · 2024Observational
- Indoor residual spraying of experimental huts in Cameroon highlights the potential of Fludora® Fusion to control wild pyrethroid-resistant malaria vectors.BMC infectious diseases · 2024Article
- Mosquitocidal effect of ivermectin-treated nettings and sprayed walls on Anopheles gambiae s.s.Scientific reports · 2024Article
- Can neonicotinoid and pyrrole insecticides manage malaria vector resistance in high pyrethroid resistance areas in Côte d'Ivoire?Malaria journal · 2024Article
- Efficacy of Pirikool® 300 CS used for indoor residual spraying on three different substrates in semi-field experimental conditions.Malaria journal · 2024Article
- Article
- Laboratory evaluation of the contact irritancy of a clothianidin solo formulation vs. clothianidin-deltamethrin mixture formulations for indoor residual spraying against pyrethroid-resistant Anopheles gambiae sensu lato.Parasites & vectors · 2024Article
- Observational
- Dramatic resurgence of malaria after 7 years of intensive vector control interventions in Eastern Uganda.medRxiv : the preprint server for health sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundScale-up of the distribution of long-lasting insecticide-treated bed nets and indoor residual spraying with insecticides over the last decade have contributed to the considerable decrease of malaria morbidity and mortality in sub-Saharan Africa. Due to the increasing pyrethroid resistance intensity and the spread of carbamate resistance in Anopheles gambiae (s.s.) mosquitoes and the limited number of insecticides recommended by the WHO for vector control, alternative insecticide formulations for IRS with long-lasting residual activity are required to sustain the gains obtained in most malaria-endemic countries.
methodsSumiShield 50WG (clothianidin 300 mg ai/m
resultsThe results showed very low toxicity from deltamethrin (mortality rates ranged between 1-40%) against host-seeking resistant Anopheles populations. SumiShield in contrast gave an overall mean mortality of 91.7% at the 120 h observation across the eight- month observation period following spraying. The residual activity measured using cone tests was over the 80% WHO threshold for 24 weeks for resistant wild Anopheles population and 32 weeks for the susceptible strain "Kisumu" after the spraying.
conclusionsSumiShield is a good candidate for IRS in areas of permanent malaria transmission and where Anopheles populations are resistant to other conventional insecticides such as pyrethroids. It would be interesting to complete experimental huts studies by assessing the efficacy and residual effect of SumiShield 50WG at community level (small-scale field testing) in an area where vectors are highly resistant to insecticides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.